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Abstract 31 
Paclitaxel loaded solid lipid nanoparticles (SLN) of behenic acid were prepared with the 32 
coacervation technique. Generally, spherical shaped SLN with mean diameters in the range 300-600 33 
nm were obtained. The introduction of charged molecules, such as stearylamine and glycol chitosan 34 
into the formulation allowed to obtain positive SLN with Zeta potential in the 8-20 mV range and 35 
encapsulation efficiency in the 25-90% range. 36 
Blood-brain barrier (BBB) permeability, tested in vitro through hCMEC/D3 cells monolayer, 37 
showed a significantly increase in the permeation of Coumarin-6, used as model drug, when 38 
vehicled in SLN. Positive-charged SLN do not seem to enhance permeation although stearylamine-39 
positive SLN resulted the best permeable formulation after 24 h.    40 
Cytotoxicity studies on NO3 glioblastoma cell line demonstrated the maintenance of cytotoxic 41 
activity of all paclitaxel-loaded SLN that was always unmodified or greater compared with free 42 
drug. No difference in cytotoxicity was noted between neutral and charged SLN. 43 
Co-culture experiments with hCMEC/D3 and different glioblastoma cells evidenced that, when 44 
delivered in SLN, paclitaxel increased its cytotoxicity towards glioblastoma cells.  45 
 46 
Abbreviations: 47 
PTX, paclitaxel; SLN, solid lipid nanoparticles; BA, behenic acid; ST, stearylamine; GCS, glycol 48 
chitosan; BBB, blood-brain barrier; GBM, blioblastoma multiforme; CNS, central nervous system; 49 
NP, nanoparticles; cationic bovine serum albumin, CBSA; NHEJ, non-homologous end joining; 50 
PK, protein Kinase; CS, chitosan; Cou-6, coumarin 6; Na-BA, sodium behenate; CHOL, 51 
cholesterol; FD, freeze-dried; DMEM, Dulbecco’s modified Eagle’s medium; NS, neurosphere; 52 
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AC, adherent cell; ATM, ataxia telangiectasia mutated; ChK2, checkpoint kinase; p-53BP1, 53 53 
binding protein 1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl-tetrazolium bromide; IF, 54 
immunofluorescence; HR, homologous recombination; TEM, transmission electron microscopy; 55 
EE, entrapment efficiency; Pgp, P-glycoprotein; MRP1, multidrug resistance related protein 1. 56 
 57 
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1. Introduction 64 
Glioblastoma multiforme (GBM) is the most common form of primary brain tumor in the central 65 
nervous system (CNS); its aggressive nature and evasiveness to treatments make it one of the most 66 
lethal cancers [1]. Current treatments for GBM provide a tumor surgical resection followed by 67 
pharmacotherapy and radiotherapy. Pharmacotherapy, directed by residual tumor cells elimination, 68 
ranges from common chemotherapeutic agents such as temozolomide to more recent anti-69 
angiogenic agents and immunotherapeutic treatments [2]. However, anti-cancer therapeutic agents 70 
have not significantly increased the median survival of GBM patients over the past 10 years. The 5-71 
year survival rate of GBM patients after treatment that includes surgical resection, radiation and 72 
chemotherapy, is 9.8%. 73 
The failure of chemotherapy is due to the inability of intravenously administered anticancer agents 74 
to reach the brain parenchyma. An endothelial cell monolayer associated with pericytes and 75 
astrocytes, known as the blood–brain barrier (BBB), separates blood from the cerebral parenchyma 76 
and prevents the penetration of drugs into the CNS. 77 
BBB is a functional unit composed by the peculiar endothelium of brain microvessels, the capillary 78 
basal lamina and the surrounding astrocytes, neurons, microglial cells and pericytes, which 79 
contribute to the maintenance of the barrier properties [3, Figure A.1]. The presence of tight 80 
junctions and adherent junctions between adjacent endothelial cells [4], the lack of fenestrations and 81 
pinocytotic vesicles [5], the abundance of efflux transporters belonging to the ATP binding cassette 82 
family on the endothelium luminal side [6] account for the low delivery of drugs, such as 83 
antineoplastic agents [7], from the bloodstream to the brain parenchima. 84 
Various invasive strategies have been developed to improve the penetration of drugs into the brain 85 
[8]. Traditional approach to overcome brain drug delivery obstacles includes direct intracerebral 86 
drug injection [9],which is associated with a high risk for the patient. 87 
Less invasive strategies have also been investigated. One approach consists in generating a transient 88 
disruption of BBB in conjunction with the systemic administration of anticancer agents. The 89 
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intracarotid administration of a hyperosmotic solution such as mannitol led to a rapid diffusion of 90 
fluid across the cerebral endothelium, moving out of the endothelial cells into the vascular lumen 91 
and inducing the opening of the tight junctions for a few hours [10]. 92 
Another approach concerns the modification of drugs in order to make them more lipophilic, 93 
improving their penetration into the brain by passive diffusion. Lipophilic analogs and prodrugs 94 
were thus developed [11]. 95 
A more recent strategy to deliver drugs to the brain is the use of colloidal polymers to form 96 
nanometer sized carriers [12]. The basic reason of common acceptance of these vehicles is due to 97 
their drug release controlled profile of  as well as to their selected targeting mechanism. Targeting 98 
action may be due to the steric hindrance created by nano-vectors: after parenteral  administration, 99 
due to steric phenomenon they conceal themselves from opsonization event induced by tissue 100 
macrophages. By this way they achieve targeting ability to the brain and partially avoid other 101 
reticuloendothelial system organs like liver, spleen, etc [13]. 102 
From the last few decades, nanoparticles (NP) have attracted considerable interest in targeting drug 103 
molecules to the brain [14]. The correct mechanism of barrier opening by NP is not exactly known; 104 
the delivered NP enter into the brain by crossing the BBB by various endocytotic mechanisms, as 105 
polymeric albumin or poly(butylcyanoacrylate) NP are reported to enter into the brain by their small 106 
size mediated endocytosis [15,16]. An increased drug retention in brain blood capillaries combined 107 
with an adsorption to capillary can increase drug transport due to an enhanced concentration 108 
gradient; an increase of BBB fluidization, an opening of tight junctions between endothelial, an 109 
inhibition of the P-glycoprotein efflux system are other possible mechanisms that can increase brain 110 
drug concentration [17]. 111 
Although NP may be designed to entrap high molecular weight or hydrophilic therapeutics, BBB 112 
retardation of drug NP entrapped is based on NP characteristics and not on the therapeutic agent 113 
[18]. 114 
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Indeed, poly(butyl cyanoacrylate) NP overcoated with 1% polysorbate 80 have been experimentally 115 
successful as brain drug delivery for doxorubicin [19] and dalargin [20], poly(lactic-co-glycolic 116 
acid) and  cetyl alcohol/polysorbate NP for paclitaxel brain delivery [21,22].  117 
In addition to BBB functional characteristics limiting permeation, brain microvasculature 118 
endothelia also present a luminal electrostatic barrier at physiologic pH. The negative electrostatic 119 
charge is created by surface expression and adhesion of the glycocalyx residues: proteoglycans, 120 
sulfated mucopolysaccharides, and sulfated and sialic acid-containing glycoproteins and glycolipids 121 
[23]. Cationic molecules have been shown to occupy anionic areas at the BBB endothelium [24] 122 
and increase BBB permeability via a presumed tight junction disruption [25]. 123 
Recent in vitro reports have demonstrated that positive-charged NP have an increased brain 124 
distribution compared to anionic and neutral NP [26]. However, there is little data regarding brain 125 
permeability of positive-charged NP. Lu et al. [27] developed and evaluated cationic bovine serum 126 
albumin (CBSA) conjugated with poly(ethyleneglycol)–poly(lactide) NP (CBSA–NP). To evaluate 127 
the effects of brain delivery, BSA conjugated with pegylated NP (BSA–NP) was used as the control 128 
group and Coumarin-6 was incorporated into the NP as the fluorescent probe. The qualitative and 129 
quantitative results of CBSA–NP uptake experiment compared with those of BSA–NP showed that 130 
rat brain capillary endothelial cells took in much more CBSA–NP than BSA–NP at 37 °C, at 131 
different concentrations and time incubations. After a dose of 60 mg/kg CBSA–NP or BSA–NP 132 
injection in mice caudal vein, fluorescent microscopy of brain coronal sections showed a higher 133 
accumulation of CBSA–NP in the lateral ventricle, third ventricle and periventricular region than 134 
that of BSA–NP. In an experimental work Lockman et al. [15] evaluated the effect of neutral, 135 
anionic and cationic charged NP on BBB integrity and NP brain permeability. Neutral NP and low 136 
concentrations of anionic NP had no effect on BBB integrity, whereas, high concentrations of 137 
anionic NP and cationic NP disrupted the BBB. The brain uptake rates of anionic NP at lower 138 
concentrations were higher than of neutral or cationic formulations at the same concentrations. 139 
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In literature, many authors studied solid lipid nanoparticles (SLN) as drug delivery systems to 140 
deliver drugs to the CNS [28,29]. SLN are disperse systems having size ranging from 1 to 1000 nm 141 
which represent an alternative to polymeric particulate carriers and are composed of physiological 142 
or biocompatible lipids or lipid molecules with a history of safe use in therapy and are generally 143 
suitable for intravenous administration. 144 
As few data are present in literature about positive-charged SLN for brain delivery, the purpose of 145 
this work will be to prepare, characterize and evaluate in vitro the potential of positive-charged SLN 146 
to vehicle paclitaxel (PTX) to the brain for GBM treatment.  147 
PTX, a diterpene isolated from Taxus brevifolia, is one of the most active chemotherapeutic agents 148 
against a wide panel of solid tumors including urothelial, breast, lung, and ovarian cancers. It has 149 
been demonstrated that PTX is effective against glioblastoma cells in vitro [30,31], however its 150 
clinical use is limited due to its poor BBB penetration capability and drug-resistance [32,33].  151 
Due to its low water solubility, PTX is formulated in a mixture of Cremophor® EL and dehydrated 152 
ethanol (50:50 v/v) a combination known as Taxol®. However, Taxol® has some severe side 153 
effects related to Cremophor® EL and ethanol [34]. Therefore, there is an urgent need for the 154 
development of alternative PTX formulations.  155 
Recently, a new solvent-free technique, defined as “coacervation”, was developed to prepare fatty 156 
acids-based SLN [35]. Briefly, a fatty acid alkaline salt micellar solution in the presence of an 157 
appropriate polymeric stabilizer was prepared; when the pH is lowered by acidification, the fatty 158 
acid precipitates as nanoparticles owing to proton exchange between the acid solution and the 159 
sodium salt.  160 
SLN were prepared using two different positive-charged substances: ST or GCS. ST possess a 161 
hydrocarbonic chain that can probably be incorporated within the lipid matrix, while its positive 162 
charge is exposed to the external surface. GCS, a chitosan derivative conjugated with ethylene 163 
glycol branches, is a water soluble at a neutral/acidic pH values polymer whose pendant glycol 164 
branches increase both the aqueous solubility of the native chitosan (CS) and provide steric 165 
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stabilization [36]. Mao et al [37] have established that CS is capable of opening the tight junctions 166 
of epithelial cells and it can improve the uptake of hydrophilic drugs including peptides.  167 
For the above mentioned purpose, PTX loaded cationic SLN were prepared and extensively 168 
characterized in vitro with regard to their physicochemical properties, their capacity to load and 169 
release PTX, their cytotoxicity and their permeability across hCMEC/D3 cell lines taken as an in 170 
vitro model of BBB.  171 
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2. Experimental 172 
2.1 Chemicals 173 
Sodium Behenate (Na-BA) was purchased from Nu-Chek Prep, Inc. (Elysian, U.S.A.), Tween®80, 174 
sodium dodecyl sulfate, Triton X-100 and cholesterol from Fluka (Buchs, Switzerland), paclitaxel 175 
(PTX) from Indena (Milan, Italy), citric acid from A.C.E.F. (Fiorenzuola d’Arda, Italy), 80% 176 
hydrolyzed PVA 9000–10000 Mw (PVA 9000), Pluronic F68, stearylamine (ST), glycol chitosan 177 
(GCS), coumarin 6 (Cou-6), triethanolamine phosphate, trehalose, penicilin-streptomycin, 178 
hydrocortisone, ascorbic acid, Hepes and b-FGF from Sigma (Dorset, UK), hydrochloric acid, 179 
sodium hydroxide and sodium phosphate monobasic from Merck (Darmstadt, Germany), 180 
Cremophor® EL from BASF (Ludwigshafen am Rhein, Germany), EBM-2 basal medium from 181 
Lonza, (Basel, Switzerland), fetal bovine serum Gold from PAA The Cell Culture Company 182 
(Pasching, Austria), rat collagen-I from Trevigen (Gaithersburg, Maryland, USA), chemically 183 
defined lipid concentrate from Invitrogen Life technologies (Carlsbad, California, USA), methanol 184 
and ethanol from Carlo Erba (Val De Reuil, France). Deionized water was obtained by a MilliQ 185 
system (Millipore, Bedford, MO).  186 
 187 
2.2 hCMEC/D3 cells 188 
hCMEC/D3 cells, a primary human brain microvascular endothelial cell line that retains the 189 
property of BBB in vitro, were cultured as reported [38]. Briefly, cells were maintained in Petri 190 
dishes coated with 150 µg/ml rat collagen-I and cultured in  EBM-2 basal medium supplemented 191 
with 5% v/v fetal bovine serum Gold, 1% v/v penicilin-streptomycin, 1.4 µM hydrocortisone, 5 192 
µg/ml ascorbic acid, 10 mM Hepes, 1% v/v Chemically Defined Lipid Concentrate, 1 ng/ml b-193 
FGF. In all the experiments cells were used between passages 29 and 34. For the permeability 194 
assays, cells were seeded at 50,000/cm² and grown for 7 days up to confluence in Petri dishes and 195 
Transwell devices (0.4 μm diameter pores-size, Corning Life Sciences, Chorges, France), with 1.5 196 
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ml/cm2 and 3 ml/cm2 of the culture medium described above in the Transwell insert and in the 197 
lower chamber, respectively. 198 
Before each experiment we measured  the transendothelial electrochemical resistance (TEER) and 199 
the permeability coefficient of dextran-FITC, [14C]-sucrose and [14C]-inulin, taken as parameters 200 
of paracellular transport across hCMEC/D3 monolayer, as described in [39]. TEER value was 201 
between 30 and 40 Ω x cm2, dextran-FITC permeability coefficient was 0.015 + 0.003 x 10-3 202 
cm/min, [14C]-sucrose permeability coefficient was 1.19 + 0.21 x 10-3 cm/min, [14C]-inulin 203 
permeability coefficient was 0.56 + 0.09 x 10-3 cm/min. These values suggested the functional 204 
integrity of BBB monolayer [38].  205 
 206 
2.3 GBM cell lines and culture conditions  207 
Primary human GBM cell lines NO3 and CV17  were obtained from primary human GBMs 208 
surgically resected at the Department of Neuroscience, Neurosurgical Unit, University of Turin, 209 
Italy. The histological diagnosis was performed according to World Health Organization (WHO) 210 
guidelines. The study was in compliance with the local institutional review board and Committee on 211 
Human Research and with the ethical human-subject standards of the World Medical Association 212 
Declaration of Helsinki Research. Written informed consent was obtained from all patients. 213 
010627 GBM cell line was a kind gift of Dr. Galli R, DIBIT San Raffaele, Milan, Italy). For 214 
cytotoxicity studies in co-culture models U87-MG cells (ATCC, Rockville, MD) were also used. 215 
By neurosphere assay, from a resected tumor tissue we obtained neurosphere (NS) or adherent cell 216 
(AC) or both cell types [40]. NS lines were cultured on Dulbecco’s modified Eagle’s medium 217 
(DMEM)/F-12 supplemented with 20 ng/ml epidermal growth factor (EGF) and 10 ng/ml basic 218 
fibroblast growth factor (bFGF); AC lines were grown on DMEM supplemented with 10% fetal 219 
bovine serum (FBS) for AC. Both cultures were maintained at 37°C and at 5% O2/CO2 in a 220 
humidified multigas Sanyo MCO-18M incubator (Sanyo Scientific, Bensenville, IL). 221 
11 
 
 All cell cultures were periodically checked for Mycoplasma contamination (e-MycoTM 222 
Mycoplasma PCR Detection kit, iNtRON Biotechnology, Korea). 223 
 224 
2.4 PTX-loaded SLN preparation 225 
Different SLN formulations were prepared (Table 1); non-charged SLN were prepared as reference 226 
to evaluate the positive-charge influence. 227 
Non-charged SLN: SLN were prepared by the coacervation method [35]. Briefly, appropriate 228 
amounts of Na-BA and PVA 9000 were dispersed in 5 ml deionized water and the mixture was then 229 
heated under 5 min-stirring (300 rpm) just above the Krafft point of Na-BA (75 °C) to obtain a clear 230 
solution (micellar solution). A selected acidifying solution (100 µl 1M NaH2PO4 + 160 µl 1M HCl) 231 
was then added drop-wise until pH 4.0 was reached. The obtained BA SLN suspension was then 232 
cooled in a water bath under 10 min-stirring at 300 rpm until 15 °C temperature was reached. SLN 233 
suspension was then again heated under stirring (300 rpm) just above the melting point of BA (80 234 
°C). Different amounts of 30 mg/ml ethanol PTX solution, heated at the same temperature of SLN 235 
suspension, were added to the warm mixture and then the sample was again cooled in a water bath 236 
under stirring at 300 rpm until 15 °C was reached. 237 
Charged SLN: SLN were prepared as described for non-charged SLN, introducing the positive-238 
charged agent as follows: 239 
- ST-SLN: a fixed amount of 30 mg/ml 2-propanol ST solution (Table 1) was added to the warm 240 
aqueous Na-BA solution just above the Krafft point of Na-BA.  241 
- GCS-SLN: an appropriate amount of GCS (Table 1) was added at the beginning of the 242 
preparation before obtaining the micellar solution. 243 
All SLN formulations were also prepared in the presence of cholesterol (CHOL-SLN): 100 or 150 244 
µl of 5 mg/ml ethanol CHOL solution were added to the micellar solution immediately before the 245 
addition of the acidifying solution.  246 
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All SLN formulations were also prepared without drug (unloaded SLN) adding the same amount of 247 
ethanol instead PTX-ethanolic solution. 248 
Fluorescent SLN to be employed in in vitro experiments were prepared using Cou-6 as fluorescent 249 
lipophilic model drug (Cou-6-CHOL-SLN). 5 ml SLN were prepared in aseptic conditions (under 250 
laminar flow airfilter starting from materials sterilized with UV or in autoclave) adding 100 µl 251 
2mg/ml Cou-6 ethanol solution after SLN fusion. The samples were then cooled in a water bath 252 
under stirring at 300 rpm until 15°C temperature was reached.SLN were lyophilized using a 253 
programmable freeze-dryer (Shin PVTFD10R, Shinil Lab, Korea) without cryoprotectant addition. 254 
Slow freezing was carried out on the shelves in the freeze dryer (shelf temperature −40 °C). 255 
Samples were lyophilized for 24 h from −40 °C to 25 °C at a 5 °C/h. increasing rate. Lyophilized 256 
products were reconstituted by magnetic stirring adding the same water amount.  257 
 258 
2.5 SLN characterization 259 
SLN shape and mean sizes were characterized by Transmission electron microscope (TEM, CM 10 260 
Philips, The Netherlands) spraying the SLN suspension on the microscope grid by means of an 261 
aerosol-sampling device. 262 
Cou-6 localization into SLN dispersion was determined using optical microscopy equipped with a 263 
fluorescent lamp (Leica DM 2500, Solms, Germany) at 1000x magnification. 264 
SLN particle sizes, polydispersity indexes (PDI) and Zeta potential were determined one hour after 265 
preparation using laser light scattering technique-LLS (Brookhaven, New York, USA). Size 266 
measurements were obtained at an angle of 90° at 25 °C using the number method. The dispersions 267 
were diluted with water for size determination or with 0.01 M KCl for Zeta-potential determination, 268 
in order to achieve the prescribed conductibility. Size measurements were also recorded diluting 269 
samples with grown medium used to culture hCMEC/D3 cells to mime the conditions under which 270 
SLN undergo in vitro experiments. For  stability studies, the samples were stored at 4°C. All data 271 
were determined in triplicate. 272 
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PTX entrapment efficiency (EE%) was calculated as the ratio between PTX amount in SLN and 273 
that in the starting micellar solution × 100. PTX EE% determination was performed as follows: 1 274 
ml SLN suspension was centrifuged for 15 min at 62,084 g, the precipitate was washed twice with 1 275 
ml ethanol:water 30:70 to eliminate adsorbed PTX. The solid residue was dissolved in 1 ml ethanol, 276 
0.5 ml water were then added to precipitate the lipid matrix and the supernatant obtained was 277 
injected in HPLC for PTX quantification.  278 
EE% was also determined after 1:100 dilution in different media to mime the dilution that SLN can 279 
undergo after administration. Briefly, 500 µl SLN were introduced in a 50 ml flask and 49.5 ml 280 
water or 0.1 M phosphate buffer pH 7.4 or 0.1 M citric acid buffer pH 5.5 were added. The 281 
suspension was stirred for 2 hours. 8 ml suspension were centrifuged for 15 min at 62,084  g and 282 
then treated as previously described.  283 
 284 
2.6 HPLC analysis 285 
HPLC analysis was performed using a LC9 pump (Shimadzu, Tokyo, Japan) with a 286 
Chromosystem™ ODS 2.5 μ 125×4.6mm column and a C-R5A integrator (Shimadzu, Tokyo, 287 
Japan); mobile phase: CH3CN:H2O 60:40 (flow rate 1ml min-1); detector: UV λ=227 nm 288 
(Shimadzu, Tokyo, Japan). Retention time was 2.6 min. 289 
The limit of quantification, defined as the lowest PTX concentration in the curve that can be 290 
measured routinely with acceptable precision and accuracy, was 0.013 µmol/ml; the limit of 291 
determination, defined as the lowest detection limit, was 0.005 µmol/ml (signal to noise>2.0). 292 
 293 
2.7 SLN and PTX stability 294 
SLN sizes and PTX EE% of samples stored at 4 °C were monitored for 90 days to study SLN 295 
physical stability and PTX chemical stability. Mean sizes were determined by LLS and PTX EE% 296 
over time was obtained as described by HPLC. 297 
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The same SLN suspensions were freeze-dried without adding any cryoprotectant (FD-SLN) using a 298 
Modulyo Freeze Dryer (Edwards Alto Vuoto, Italy). The resulting samples, rehydrated with the 299 
same water amount, were also characterized by size, Zeta potential and EE% determination. 300 
 301 
2.8 PTX in vitro release 302 
In vitro release of PTX was determined using the non-equilibrium dialysis method [41]. A 303 
multicompartmental rotating cell system consisting of donor and receptor compartments of equal 304 
volume (1.5 ml) separated by a dialysis membrane (cut-off 12,000 Da) was used. Receiving 305 
medium was 0.1 M phosphate buffer (pH 7.4) containing 0.1% v/v Tween®80. Solution of PTX in 306 
receiving medium and SLN suspensions were used as donor formulations. At fixed times, the 307 
receptor solution was tipped out and used for HPLC analysis and the cell was refilled with fresh 308 
receiving medium. Drug concentration was determined by HPLC. The results were evaluated as 309 
PTX apparent permeability constant (Kdapp [cm h−1]) calculated from the slope of the straight line 310 
obtained by plotting the amount of PTX diffused from the donor formulation versus time, assuming 311 
pseudo zero-order kinetics. 312 
 313 
2.9 Permeability of SLN through hCMEC/D3 cell monolayer 314 
hCMEC/D3 cells, seeded as reported above in Transwell devices, were incubated at day 7 with  315 
SLN 2, SLN 9, SLN 15 loaded with Cou-6, f o r  0 . 5 ,  3  a n d  2 4  h  i n  t h e  T r a n s w e l l  316 
i n s e r t . The amount of SLN added was 100 µl diluted with 900 µl of medium. This dilution of 317 
SLN was the highest concentration devoid of cytotoxic effects on hCMEC/D3 cells, as previously 318 
reported [42]. In parallel, a set of Transwell inserts were incubated with Cou-6  aqueous  suspension  319 
obtained  with  PVA  9000  as  suspending agent,  containing  the  same concentration of Cou-6 320 
present in SLN.  At the end of the incubation time, the medium in lower chamber was collected, 321 
diluted 1: 20 into ethanol, sonicated with 10 bursts of 1 s to disrupt SLN,  and centrifuged at 62,084 322 
g for 5 min, to pellet debris. The dilution of the medium was necessary to obtain a fluorescence 323 
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falling in the detection range of the LS-5 spectrofluorimeter (PerkinElmer, Waltham, MA), used to 324 
measure the fluorescence of Cou-6. 325 
Excitation and emission wavelengths were 485 ± 20 nm and 528 ± 20 nm, respectively. The 326 
fluorescence of Cou-6 at t0 in the upper chamber, was considered 100%. The fluorescence of Cou-6 327 
measured in the medium collected from the lower chamber was expressed as percentage of 328 
fluorescence in the upper chamber at t0. The fluorescence of the medium without Cou-6 was 329 
considered as blank and was subtracted from the fluorescence of all the other experimental 330 
conditions.  331 
To measure the amount of Cou-6 adsorbed on the Transwell membrane, Cou-6, either free or loaded 332 
in SLN, was added in empty Transwells in the same experimental conditions of the Transwells 333 
containing hCMEC/D3 cells, then the medium from the insert and the lower chamber was removed; 334 
the Transwell membrane was washed with PBS and 0.5 ml ethanol was added to solubilize the  335 
Cou-6  adsorbed on the membrane. The solution was collected and its fluorescence was read as 336 
reported above. The fluorescence was always less than 4% of the fluorescence measured in the 337 
lower chamber medium in all the experimental conditions, suggesting that such very low absorption 338 
of Cou-6 on the Transwell insert did not influence the results of the permeability assays.  339 
The level of significance was determined by a Student’s t test. Statistical significance was defined 340 
as p < 0.001. 341 
 342 
2.10 In vitro cytotoxicity assay 343 
For cytotoxicity studies, NO3 cells (both NS and AC) and CV17 NS were used at various passage 344 
numbers between 20 and 30, whereas 010627 cells (both NS and AC) were used at passage 345 
numbers between 160 and 180. 346 
Free PTX (Sigma Aldrich Co., St. Louis, MO, USA) was dissolved in 100% DMSO for stock 347 
solutions and dilutions for cell treatments were made extemporaneously in culture medium, so that 348 
the final concentration of DMSO never exceeded 0.3% (v/v).  349 
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Cell lines were treated for 72 h with increasing doses (20, 100, 500, 1400 nM) of free PTX. 350 
After exposure the cytotoxic effect of free Paclitaxel (PTX) and PTX-loaded SLN against tumor 351 
cells was evaluated assessing the number of viable cells by the Trypan blue dye exclusion test, 352 
using a TC20 automated cell counter (Bio-Rad, Berkeley, CA, USA). As for AC, results were 353 
confirmed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay 354 
(Roche, Diagnostic Corporation Indianapolis, IN, USA) [43].  355 
For Trypan blue assay, cells were plated at a density of  200 x 103 cells in 5 ml medium in a 25 cm2 356 
flask and treated with PTX (free in solution or encapsulated in SLN2, SLN9 or SLN15) at 37°C in 357 
5% O2/CO2 for different times (24 and 72 h). Stock solutions were diluted extemporaneously in 358 
fresh medium at the desired concentration and administered to cells.  359 
Cytotoxicity was expressed as number of surviving cells as percentage of control (untreated cells). 360 
For MTT assay, cells were seeded in 96-well plates (1 x 104 cells/well in 100 µl medium) and 361 
treated with the different concentrations and times above indicated of the drug (free or 362 
encapsulated) at 37 °C in 5% O2/CO2. The medium with the SLN was replaced with fresh medium 363 
and 10 µl of MTT solution (5mg/ml) were added to each well and incubated for 4 h at 37 °C. The 364 
extent of cell viability is indicated by mithocondrial conversion of yellow MTT, a tetrazole, to 365 
purple formazan by the living cells. Formazan crystals were solubilized overnight in 10% sodium 366 
dodecyl sulfate (SDS), 0.01 M HCl and optical density was measured at 570 nm (test wavelength) 367 
and 660 nm (reference wavelength) using a microplate spectrophotometer (Synergy HT, BioTek 368 
Instruments Inc., Winooski, VT, USA). Cell viability was expressed as a percentage of the 369 
absorbance measured in the treated cells compared to the control (untreated cells). All experiments 370 
were performed in quadruplicate.  371 
The concentration of free PTX which caused a 50% cell growth inhibition (IC50) compared with 372 
untreated controls, was calculated by non-linear regression for each cell line. 373 
To investigate the cytotoxic effect of PTX incorporated in SLN, a drug concentration of 100 nM 374 
was chosen for the following in vitro experiments. 375 
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Cell viability was also measured after treatment with unloaded SLN (SLN2, SLN9 and SLN15) at 376 
the highest SLN concentration used for the study, i.e. 0.1% w/v.  377 
The level of significance was determined by a two-tailed Student’s t test. Statistical significance 378 
was defined as p < 0.05 or p < 0.01. 379 
 380 
2.11 DNA damage/repair study by Immunofluorescence (IF)  381 
The occurrence of a DNA damage after SLN treatment was investigated through the analysis by IF 382 
of γ-H2AX histone, that localizes at sites of DNA fragmentation as subnuclear foci. 383 
The cell response to DNA insults was studied monitoring the activation of p-ATM, p-Chk2 and p-384 
53BP1. HR or NHEJ repair system activities were analyzed through RAD51 or Ku70/Ku80 and 385 
DNA-PKcs proteins respectively. After 72 h treatment with unloaded SLN (SLN9) or with 100 nM 386 
PTX-loaded SLN9, cells were fixed for 20 minutes with 4% paraformaldehyde at room 387 
temperature, rinsed three times with PBS, blocked/permeabilized with PBS containing 2% of the 388 
appropriate serum and 0.1% Triton X-100 for 30 minutes and stained with the following primary 389 
antibodies: mouse anti-γ-H2AX (Ser139), mouse anti-p-ATM (Ser1981) (both from Millipore), 390 
rabbit anti-p-Chk2 (Thr68) (Cell Signaling Technology), rabbit anti-p-53BP1 (Ser25) (Bethyl 391 
Laboratories), mouse anti-RAD51, mouse anti-DNA-PKcs and mouse anti-Ku70/Ku80 (all from 392 
NeoMarkers). Negative controls were obtained by omitting the primary antibody. Alexa Fluor® 393 
488-AffiniPure goat anti-rabbit IgG and Alexa Fuor® 594-AffiniPure rabbit anti-mouse IgG 394 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) were used as secondary 395 
antibodies. Cell nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) and 396 
observations were made under a Zeiss Axioskop fluorescence microscope (Karl Zeiss, Oberkochen, 397 
Germany) equipped with an AxioCam5MR5c and coupled to an Imaging system (AxioVision 398 
Release 4.5; Karl Zeiss). 399 
 400 
2.12 Specimen preparation for transmission electron microscopy (TEM) 401 
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Analysis by TEM was employed in order to get information on the possible ultrastructural 402 
modifications of cells treated with empty and PTX-loaded SLN. NO3 NS and AC lines were used 403 
for the investigation. 404 
For transmission electron microscopy, untreated cells, cells treated with unloaded SLN15 and cells 405 
treated with 100 nM PTX-loaded SLN15 for 24 h were collected, pelleted by centrifugation and 406 
then fixed with 2.5% glutaraldehyde prepared in 0.1 M phosphate buffer at 4 °C. Samples were 407 
post-fixed with 1% osmium tetroxide for 2 h, dehydrated in a graded acetone series and embedded 408 
in the Epon 812 epoxy resin. Ultrathin sections were prepared using an ultracut microtome 409 
(Reichert-Jung, Germany), collected on copper grids, stained with both lead citrate and uranyl 410 
acetate, and then observed with a Philips CM-12 transmission electron microscope. 411 
 412 
2.13 Glioblastoma cell cytotoxicity in co-culture models 413 
In co-culture experiments, 500,000 glioblastoma cells (i.e. the U87-MG cell line and the primary 414 
human glioblastoma cells CV17 and 01010627)  were added in the lower chamber of Transwells 4 415 
days after seeding hCMEC/D3 cells in the upper chamber of Transwells. After 3 days of co-culture 416 
the medium of the upper chamber was replaced with fresh medium, with or without free PTX or 417 
PTX-loaded SLN (SLN 2) at different concentration (20, 50, 100, 200, 500 nM) for 24 h, as 418 
detailed under results. 419 
To measure the viability of glioblastoma cells co-cultured with hCMEC/D3 cells, extracellular 420 
medium of glioblastoma cells was collected and centrifuged at 12,000 g for 15 min to pellet cellular 421 
debris, whereas cells were washed with fresh medium, detached with trypsin/EDTA (0.05/0.02% 422 
v/v), re-suspended in 0.2 ml of 82.3 mmol/l triethanolamine phosphate-HCl (pH 7.6) and sonicated 423 
on ice with two 10 s bursts (Labsonic sonicator, 100 W). LDH activity was measured in the 424 
extracellular medium and in the cell lysate: 50 μl of supernatant from extracellular medium or 5 μl 425 
of cell lysate were incubated at 37 °C with 5 mmol/l NADH. The reaction was started by adding 20 426 
mmol/l pyruvic acid and was followed for 6 min, measuring absorbance at 340 nm with Packard 427 
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EL340 microplate reader (Bio-Tek Instruments, Winooski, VT). The reaction kinetics was linear 428 
throughout the time of measurement. Both intracellular and extracellular enzyme activity was 429 
expressed in μmol NADH oxidized/min/dish, then extracellular LDH activity was calculated as 430 
percentage of the total LDH activity in the dish. 431 
The level of significance was determined by a Student’s t test. Statistical significance was defined 432 
as p < 0.05, p < 0.02,  p < 0.01, p < 0.005 or p < 0.001.  433 
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3. Results and discussion 434 
As described in the introduction chapter, BBB is a physical barrier characterized by tight 435 
intracellular junctions and by the absence of fenestrations that limit permeability for therapeutic 436 
molecules with no exception for molecules in the glioblastoma treatment. The use of drug-loaded 437 
nanoparticles could be a winning strategy if an active targeting and a suitable drug concentration to 438 
the brain could be obtained, provided small-sized hydrophilic vehicles are achieved to prevent rapid 439 
degradation by reticuloendothelial system and carriers with proper superficial characteristics are 440 
coupled.  441 
Moving from this background, SLN were prepared using the coacervation method which uses 442 
hydrophilic polymeric as stabilizers able to confer hydrophilic surface to SLN. Further to a 443 
cytotoxicity study against hCMEC/D3 cells relating to different fatty acids [40], BA was chosen as 444 
lipid matrix. In order to take advantages of possible interaction between BBB negative charges and 445 
surface positive-charged SLN, two positive charged molecules currently used in literature were 446 
introduced in the SLN preparation: ST [44] and GCS [36]. As antineoplastic model drug PTX was 447 
chosen, a lipophilic molecule suitable to be entrapped in SLN matrix.  448 
Preliminary formulation studies (data not reported) demonstrated the need to modify the preparation 449 
procedure to obtain higher drug EE% by introducing PTX after SLN melting instead of adding it to 450 
the micellar solution; probably the high PTX lipophilicity does not allow its distribution within 451 
micelles, while promoting its solubilization in the molten lipid.  452 
 453 
3.1 SLN characterization 454 
In Table 1 compositions of PTX-loaded SLN are reported. SLN composition was the result of a 455 
preliminary screening carried out in a previous work [45].  456 
In Table 1 ST-SLN and GCS-SLN compositions are also reported. Different formulations were 457 
obtained varying the amount of PVA 9000, ST, GCS or PTX in order to obtain the most suitable 458 
PTX vehicle as concerns Zeta potential, mean sizes, EE%, over time stability. In order to improve 459 
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SLN stability, CHOL was also added. As reported in literature [46] high CHOL/lipid ratio matrix 460 
reduced mean diameters of SLN prepared from emulsion. This led to a rigid surfactant layer with 461 
decrement in van der Waals attraction and promotion of net repulsion forces between oil droplets; 462 
therefore, agglomeration and coalescence of small oil droplets were reduced. In addition, the 463 
interaction between CHOL and surface active agent might increase the surface curvature of oil 464 
droplets consequently leading to small size of SLN after cooling down. A similar behavior can be 465 
hypothesized also in SLN obtained by coacervation. In the present experimental conditions, CHOL 466 
probably might interact with Na-BA at the interface of micelles. 467 
In Table 1 SLN, ST-SLN and GCS-SLN mean diameter and Zeta potential are reported. Most SLN 468 
tested had sizes below 600 nm. In the neutral SLN series (SLN 0-3), increasing the amount of PTX 469 
no changes in particles dimension were noted; different behavior was noted in the case of charged 470 
SLN. In the ST-SLN series (SLN 4-10) an increase in diameter sizes can be noted when ST or PTX 471 
amounts were increased or when CHOL was introduced in the formulation. Nevertheless the 472 
presence of CHOL was essential to SLN stability: in the absence of CHOL, ST-SLN and GCS-SLN 473 
showed a sudden increase in mean size immediately after preparation. Instead, in the GCS-SLN 474 
(SLN 11-17) series a slightly decrease in SLN size was obtained increasing the GCS amount and a 475 
more marked increase was noted when a great amount of stabilizer (PVA) was used. Also in this 476 
case the presence of CHOL was necessary to formulations stability; the addition of this component 477 
led to a decrease in mean diameter and the smallest SLN were obtained using 50 mg (1% w/w) 478 
PVA (SLN 17).  479 
The dissimilar influence of ST and GCS on ST-SLN and GCS-SLN sizes might be due to different 480 
positioning of both charged molecules: probably, lipophilic ST chain was incorporated in the lipid 481 
matrix while GCS was mainly adsorbed to the external surface of nanoparticles. 482 
Size measurements were employed also diluting the samples with growth medium used in the in 483 
vitro experiments in order to verify SLN sizes when they are tested in vitro. The growth medium 484 
does not seem to influence SLN dimensions: all SLN have maintained their size (data not reported).    485 
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In Figures 1a and 1b TEM PTX-SLN2 images at different magnifications were reported. The SLN 486 
have spherical shape and sizes between 300 and 500 nm. The drug introduction does not seem to 487 
affect shape and size (data not reported). Similar characteristics were obtained also with SLN9 and 488 
SLN15. 489 
The observation of Cou-6-SLN nanosuspensions under optical microscope confirmed both the 490 
spherical shape and the dimensional range of the particles. The use of fluorescent light allowed to 491 
locate Cou-6 in SLN nanosuspensions: homogeneous dispersions of fluorescent nanoparticles were 492 
observed with all formulations (data not shown). 493 
In Table 1 also Zeta potential values are reported. All GC or ST-containing formulations showed 494 
positive charge with values in the 7.6 - 23.8 mV range. ST-SLN presented Zeta potential ranging 495 
from 7 to 15 mV (depending on ST amount used); these values are smaller than those of GCS-SLN 496 
and those of SLN containing the same ST percentages but prepared with methods other than 497 
coacervation [41]; probably PVA 9000 used as stabilizer locates itself externally thus partially 498 
screening the ST positive charge. 499 
In GCS-SLN series, Zeta potential values confirmed the external positioning of the polymer: 500 
probably positively-charged GCS interacted with carboxylate groups on SLN surface, conferring 501 
them a positive charge. The values were influenced by GCS amount: by increasing the polymer an 502 
increase of Zeta potential from 16.9 mV to 23.8 mV was noted; the presence of CHOL and the PTX 503 
amount variation did not seem to influence this parameter.    504 
In Table 2 the amount of PTX in SLN is expressed as EE% and as loading (mg PTX/mg BA). 505 
Almost all tested SLN showed a good PTX loading capacity; in particular, in neutral SLN series 506 
(SLN 0-3) PTX EE% did not significantly vary increasing the drug amount, while drug loading was 507 
increased over twice folds. In the ST-SLN series (SLN 4-10), PTX EE% was significantly 508 
influenced by several factors. Increasing ST amounts determined a reduction of PTX EE% (SLN 5) 509 
which was partially counteracted by the presence of CHOL (SLN 6) probably as a consequence of a 510 
23 
 
hardened structure of SLN surface. Also PVA amount seemed to be relevant in influencing PTX 511 
EE%, as higher PVA concentrations determined a reduction in PTX EE%. 512 
In GCS-SLN series (SLN 11-17), EE% and PTX loading ranged from 24% to 83% and from 1.4 to 513 
5.0 mg/mg BA respectively. Also in this series PTX EE% was strongly influenced by PVA 9000 514 
amount: when the highest stabilizer amount was used (SLN 14), a dramatic decrease in drug EE% 515 
up to 24% can be noted; probably PVA 9000 formed micelles in aqueous phase able to solubilize 516 
PTX. CHOL introduction enhanced PTX EE% from 52% to 75% particularly in SLN prepared with 517 
50 mg PVA 9000. On the contrary, GCS amount variations did not seem to affect drug EE%.  518 
To mime SLN behavior after administration when they are diluted in physiological fluids, drug 519 
EE% was determined also after 1:100 dilutions. When water was used as dilution medium,  EE% 520 
remained almost unvaried in all ST-SLN (±1%), except in SLN 15 in which a 10% decrease was 521 
registered. Probably, in GCS-SLN, PTX is partially trapped in GCS chains located on SLN surface 522 
and therefore it might be released upon high dilutions. To evaluate the influence of different 523 
dilution media, SLN 9, which were chosen as those having the best properties for our experimental 524 
purposes, were diluted also by pH 7.4 PBS and pH 5.5 citric buffer. No significant variation was 525 
noted upon dilution by pH 7.4 PBS (±1%),  while a certain PTX amount was released when 0.1 526 
citric pH 5.5 buffer was used, that mimed the lysosomial environment: the EE% decreased from 527 
92% to 77% and this could be due to a PTX slow release.   528 
 529 
3.2 SLN and PTX stability 530 
The studies were carried out only on SLN giving the best results concerning sizes and EE%. The 531 
chosen formulations were analyzed to verify their stability overtime. The results are reported in 532 
Table 3. SLN 9 showed a great increase in mean diameter (up to 1500 nm) after 30 days, while only 533 
a slight decrease occurred in EE%. The  poor dimensional stability of SLN 9 could be due to their 534 
low Zeta potential (about 9 mV) which is probably not sufficient to prevent SLN aggregation. On 535 
the other hand, GCS-SLN (SLN 15, 16, 17) showed a higher dimensional stability although a 536 
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gradual increase in mean diameter and a gradual decrease in Zeta potential were registered due 537 
probably to a slow solubilization of the external GCS coating in the aqueous phase. 538 
To overcome the poor stability of SLN suspension and to find an optimal storage method, they were 539 
submitted to freeze drying. In Table 4 SLN sizes after freeze-drying were reported. The freeze-540 
drying process was carried out without adding any cryoprotectant; in fact in a previous work [45] 541 
PVA 9000 was found to be able to protect SLN during freeze-drying as well as 2% threalose.  542 
The characterization of resulting SLN suspensions showed a mean diameter increase of all SLN 543 
analyzed probably due to a partial SLN aggregation. This increase was about 300 nm in SLN with 544 
ST while only a slight variation was registered in SLN with GCS; probably also GCS, positioning 545 
externally, could behave as cryoprotectant preventing nanoparticles aggregation. The smallest 546 
increase (about 40 nm) was noted when higher amounts of stabilizer were used. EE% was kept 547 
constant in almost all preparations; an increase in EE% (from 75% up to 89%) was registered in 548 
SLN 17 that presented a higher amount of free PTX: probably during freeze-drying a part of free 549 
PTX was internalized or absorbed onto nanoparticles.   550 
 551 
3.3 Determination of PTX release 552 
In Figure 2 PTX release plots from SLN using the dialysis method were reported. In this experiment 553 
drug diffusion through the dialysis membrane was influenced by drug release rate from SLN. As it 554 
can be seen, PTX was released very slowly from SLN: less than 1% PTX was released from SLN 555 
formulations in 12 hours while, at the same time, about 40% PTX diffused from PTX solution. This 556 
slow release could confirm PTX incorporation into SLN. From the Kd app data it could be seen as 557 
PTX release from GCS-SLN was still slower than from ST-GCS; these results could be the 558 
confirmation that GCS formed an external coating that further limited drug release.  559 
 560 
3.4 Permeability of SLN across BBB  561 
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As shown in Figure 3, the permeability of free Cou-6 across the hCMEC/D3 monolayer 562 
remained very low at all the time points considered; the permeability of Cou-6-loaded SLN was 563 
similar to that of free Cou-6 after 0,5 h, but became significantly higher after 3 h and 24 h. 564 
Apparently there were no differences in the permeability of uncharged SLN (SLN 2) versus 565 
positively charged SLN (SLN 9 and SLN 15), although SLN 9 resulted the best permeable 566 
formulation after 24 h. 567 
 568 
3.5 In vitro cytotoxicity studies 569 
To assess the sensitivity of the five malignant glioma cell lines to PTX, we treated previously the 570 
cells with Cremophor® EL:ethanol 50:50 drug solution (free PTX) at concentrations ranging from 571 
20 nM to 1.4 µM for 72 h.  572 
After different exposure times both MTT and trypan blue assays were performed. PTX was able to 573 
block in vitro cellular proliferation in a dose-dependent manner; it inhibited clonogenic growth of 574 
NS (Figure 4a−4d) and hindered adhesion process in AC (Figure 4e−4i).  575 
The growth inhibitory effect was more evident on AC than on NS.  576 
The IC50 values of free PTX at 72 h for the three NS cell lines studied were < 20 nM; for the two 577 
AC lines were < 15 nM (Figure 5). Consequently, drug concentration of 100 nM was employed for 578 
the following experiments with PTX incorporated in SLN. At this dosage, a statistically significant 579 
decrease of cell viability was caused by PTX compared with untreated cells, both as free drug and 580 
as SLN-carried, and this effect increased prolonging drug exposure time from 24 to 72 h. It was 581 
observed that also PTX encapsulated in SLN caused inhibition of sphere formation in the NS 582 
cultures (Figure 4e) and interfered with cell adhesion in AC cultures (Figure 4l).  583 
Graphs in Figure 7 show cell viability of NO3 line after the treatments: as regards NS, the viable 584 
cell number decreased to 60-70% after 24 h treatment with the different PTX-SLN (Figure 6a) and 585 
to 30-40% after 72 h treatment (Figure 6b). At 24 h free PTX and all PTX-SLN gave a cytotoxicity 586 
statistically different from control, while only SLN 2 produced an increase in cytotoxicity 587 
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significantly different from that of empty SLN 2. Prolonging the incubation time, also SLN 9 were 588 
significantly different from the corresponding empty SLN. 589 
The reduction of viability of AC was about 10-15% higher than the one of NS (Figure 7). An 590 
analogous behavior of PTX-SLN 2 and PTX-SLN 9 was noted already after 24 h incubation, while 591 
after 72 h all SLN under study produced a cytotoxicities significantly different from those produced 592 
by the corresponding empty SLN.  The cytotoxicity of PTX incorporated in SLN appeared similar 593 
or even slightly higher in comparison with the one of free drug solution. In particular, SLN2 seemed 594 
to enhance growth inhibitory activity of PTX on NS lines, while SLN 9 did it on AC lines. 595 
The results slightly varied in the other cell lines (data not shown), but the cytotoxic activity of PTX-596 
loaded SLN remained always equal or greater compared with free drug. SLN 2 and SLN 9 appeared 597 
as the most effective carrier formulations. 598 
Control experiments demonstrated that the exposure of the cells with the unloaded SLN at the 599 
highest SLN concentration used for the study determined a mild reduction of cell viability too, 600 
mostly on AC. Unloaded SLN 2 formulation displayed the smallest cytotoxic effect, while unloaded 601 
SLN15 had a more accentuated action on cell proliferation.  602 
Treatment with PTX vehicle (50:50 v/v mixture of Cremophor® EL and ethanol) at the same 603 
concentrations used for drug solutions showed a slight cytotoxicity too (data not reported).  604 
Our results suggest that, first of all, incorporation of PTX in SLN did not alter its cytotoxic 605 
capability and that these carriers, thanks to a good cell membrane permeation, are able to efficiently 606 
transport the drug inside the cells. Encapsulation into SLN appeared even to enhance the growth 607 
inhibitory effect of PTX on GBM cell lines.  608 
In conclusion, loading of PTX in SLN seems to sensitize cells and to decrease their resistance to the 609 
drug. 610 
 611 
3.6 Study of PTX-SLN cytotoxic effect by TEM 612 
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The observation by TEM enabled to evaluate the ultrastructural alterations of cells after exposure to 613 
SLN. The analysis revealed that the administration of unloaded SLN 15 didn’t cause modifications 614 
to the cell morphology both in NS and in AC. Cells treated with empty SLN maintained unchanged 615 
nucleus, ergastoplasma, Golgi apparatus and mithocondria (Figure 8a). 616 
On the contrary, 24 h exposure to SLN loaded with 100 nM PTX induced severe alterations of the 617 
cellular morphology that included cytoplasmic accumulation of vacuoles, loss of mitochondrial 618 
ridges and finally mithocondrial lysis (Figure 8b-8f). The vacuoles became gradually larger and 619 
confluent and in some cases they blended and formed autophagolysosomes surrounded by a 620 
membrane. Cytoplasmic rarefaction, glycogen accumulation and destruction of all organelles 621 
suggested a typical regressive apoptotic pattern. Only in some areas there was evidence of SLN 622 
residues. These results indicate an evident cell damage caused by the PTX vehicled in the SLN. 623 
 624 
3.7 DNA damage and repair response induced by PTX-SLN treatment 625 
In response to DNA damage caused by genotoxic agents, the eukaryotic cell activates a complex  626 
checkpoint/repair pathway in order to repair the lesion before replication. The signalling involves 627 
the recruitment of the sensor protein kinase ataxia telangiectasia mutated (ATM), that initiates a 628 
transduction cascade phosphorylating downstream effectors, including H2AX histone, 53 binding 629 
protein 1 (53BP1) and the checkpoint kinases 1 and 2 (Chk1 and Chk2). When checkpoints are 630 
activated, the cell cycle is halted to allow DNA repair. If the damage is too severe, repair fails and 631 
the cell enters into apoptosis [47]. Two are the major pathways used by mammalian cells to repair 632 
double strand break damage: the homologous recombination (HR), which takes place during the S 633 
and G2 phases and is driven mainly by RAD51 protein, and the non-homologous end joining 634 
(NHEJ), which occurs during G0 and G1 phases. The key NHEJ effector is DNA-dependent protein 635 
kinase (DNA-PK), which consists of a regulatory subunit (Ku70/Ku80 heterodimer) and a catalytic 636 
subunit (DNA-PKcs) [48]. In glioma cells, increased DNA damage response and repair ability 637 
contribute to determine the radio- and chemoresistant phenotype of these cells [49]. 638 
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After glioma cell treatment for 72 h with relatively high concentration (100 nM) of free PTX we 639 
observed a moderate activation of checkpoint and repair proteins. A mild expression of all markers, 640 
was found both in NS and in AC (data not shown), indicating that this drug is able to induce 641 
genotoxic lesions. 642 
Even after NO3 cell line treatment with PTX carried by SLN, we found the presence of γ-H2AX 643 
positive-nuclei and a moderate expression of all sensors and effectors of checkpoint/repair pathway, 644 
both in NS (Figure 9a-9g) and in AC (Figure 9l-9q), demonstrating that the encapsulated drug 645 
maintains the ability to induce a DNA strand break damage in the glioma cell lines. As already 646 
observed for the free drug, mostly on AC lines, several cells treated with PTX-SLN appeared 647 
blocked in metaphasis (Figure 9i) and presenting a strong expression of the checkpoint/repair 648 
proteins (p-ATM, p-Chk2, p-53BP1, γ-H2AX, DNA-PKcs). It seemed from these findings that cells 649 
try to repair the genotoxic lesions mainly through the NHEJ system. Untreated cells were negative 650 
for all markers (inserts in Figure 9a and 9i are examples for p-ATM expression). 651 
After exposure of cells to unloaded SLN for 72 h we did not observe positivity of any 652 
checkpoint/repair protein (panels h and r of Figure 9 are examples for p-ATM expression). 653 
 654 
3.8 Effective cytotoxicity of paclitaxel-loaded SLN against glioblastoma cells in co-culture models. 655 
The cytotoxicity of PTX-loaded SLN on glioblastoma cells was finally compared with that of free 656 
PTX in co-culture models of hCMEC/D3 cells  and glioblastoma cells. As shown in Figures 10, 657 
11 and 12, free PTX induced a dose-dependent increase of cytotoxicity in all the glioblastoma cell 658 
lines; PTX-loaded SLN followed a similar trend and showed – at the same concentration – higher 659 
efficacy than the free drug. Also the toxicity on hCMEC/D3 cells increased dose-dependently, 660 
without significant differences between free PTX and PTX-loaded SLN (Figure 13). 661 
By comparing the cytotoxicity profile on glioblastoma cells and hCMEC/D3 cells, we can state that 662 
PTX-loaded SLN achieves significant toxicity against tumor cells at concentrations that are not 663 
toxic for BBB cells. To obtain the same degree of cytotoxicity on glioblastoma cells, free PTX 664 
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should be used at concentration that are unacceptably toxic for brain microvascular endothelial 665 
cells. The different efficacy of free versus SLN-loaded PTX can be explained by the increased 666 
permeability of the latter through the BBB monolayer. PTX is a known substrate of P-glycoprotein 667 
(Pgp) [50], which is abundant on the luminal side of BBB cells [51]; therefore, it is a poorly 668 
delivered drug into the brain parenchima. Its loading within SLN may represent a valid strategy to 669 
overcome the efflux by Pgp at BBB levels.  670 
In addition, also glioblastoma has been reported to be rich of Pgp [52] and multidrug resistance 671 
related protein 1 (MRP1) [53], a second protein that actively effluxes PTX [50], limiting its 672 
intracellular accumulation and toxicity. Therefore, a lower accumulation and toxicity of paclitaxel is 673 
expected within glioblastoma cells. The loading within SLN may promote a faster uptake and/or a 674 
lower efflux by Pgp and MRP1 from glioblastoma cells as well. Therefore, the loading in SLN may 675 
represent a valid strategy to simultaneously bypass the drug efflux at BBB and glioblastoma levels.    676 
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4. Conclusion 677 
The fatty acid coacervation technique, a solvent free method, was used to prepare PTX-loaded SLN. 678 
The use of positive-charged molecules, such as ST and GCS, allowed to obtain positive SLN with 679 
sizes in the 300-600 nm range and PTX EE% in the 25-90% range.  680 
Permeability studies through  hCMEC/D3 cells monolayer, assumed as in vitro model of the BBB, 681 
showed a significantly increase in the permeation of Cou-6, used as model drug, when vehicled in 682 
SLN; no significantly differences in the permeability of uncharged SLN versus positively charged 683 
SLN were noted after 24 h. 684 
Cytotoxicity studies on NO3 glioblastoma cell line demonstrated the absence of toxicity of 685 
unloaded SLN 2 and 9 and the preservation of cytotoxic activity of PTX-loaded SLN that remained 686 
always equal or greater compared with free drug. 687 
In co-culture experiments with hCMEC/D3 and different glioblastoma cells, it was demonstrated 688 
that, when delivered in SLN, PTX increased its cytotoxicity towards glioblastoma cells, because of 689 
its increased permeation through the endothelial cell monolayer. 690 
According to these in vitro results, the positive charge did not seem essential to enhance PTX brain 691 
uptake but fundamental seem to be the PTX encapsulation into SLN. 692 
Further i.v. administration of PTX-loaded SLN in rats are in progress to confirm the suitability of 693 
SLN in enhancing PTX overcoming of the BBB.  694 
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FIGURE CAPTIONS 834 
 835 
Figure A.1: Anatomical structures composing the BBB. AJs: adherent junctions. TJs: tight 836 
junctions. ABC: ATP binding cassette transporters. 837 
 838 
Figure 1: TEM images. a) 2200X magnification; b) 8900X magnification. 839 
 840 
Figure 2: PTX release plots from nanoparticles using the dialysis method 841 
 842 
Figure 3: Cou-6 permeability 0.1% dilution. * p < 0.001 843 
 844 
Figure 4: Effect of 72 h treatment with increasing doses (100, 500, 1400 nM) of free and 100 nM 845 
SLN10-encapsulated PTX on NO3 NS (b−e) and NO3 AC (g−k) growth. Control cells (a, f) did not 846 
receive any treatment. All 200x magnification. 847 
               848 
Figure 5: Cytotoxicity of free PTX on NS (A) and AC (B) of NO3 glioma cell line at various 849 
dosages of drug (20, 100, 500, 1400 nM) after 72 h treatment. 850 
 851 
Figure 6: a) cell viability of NO3 NS after 24 h treatment; b) cell viability of NO3 NS after 72 h 852 
treatment + p < 0.05 vs CTRL; * p < 0.05 PTX-SLN vs SLN; ++ p < 0.01 vs CTRL; ** p < 0.01 853 
PTX-SLN vs SLN 854 
 855 
Figure 7: a) cell viability of NO3 AC after 24 h treatment; b) cell viability of NO3 AC after 72 h 856 
treatment ++ p < 0.01 vs CTRL; * p < 0.05 PTX-SLN vs SLN; 857 
 858 
38 
 
Figure 8: TEM of NS after treatment with SLN15 at 15000 x. (a) After 24 h treatment with 859 
unloaded SLN15.  (b) After 6 h treatment with 100 nM PTX-loaded SLN15 (c) After 24 h treatment 860 
with 100 nM PTX-loaded SLN15 (d) Id, large vacuoles surrounded by a membrane, (e) Id, 861 
autophagolysosomes, 15000 x. (f) Possible remnants of SLN (20000 x). 862 
 863 
Figure 9: Expression by IF of checkpoint/repair proteins in NO3 glioma cells after 72 h treatment 864 
with 100 nM PTX-loaded SLN10: p-ATM, 200x (a), γ-H2AX, 200x (b), p-Chk2, 200x (c), p-865 
53BP1, 200x (d), DNA-PKcs, 200x (e), Ku70/80, 200x (f), RAD51, 200x (g) in NS; AC arrested in 866 
metaphases, DAPI, 200x (j); p-ATM, 200x (k), γ-H2AX foci, 400x (i), p-Chk2, 200x (l), p-53BP1, 867 
200x (m), DNA-PKcs, 200x (n), RAD51, 200x (o) in AC; nuclei counterstained with DAPI. 868 
Negative reaction for p-ATM in untreated NS and AC, respectively (upper and lower left inserts of 869 
panels a and i) and in NS and AC treated with unloaded SLN for 72 h (h and p); nuclei 870 
counterstained DAPI, 200x. 871 
 872 
Figure 10: cytotoxicity against CV17 cells. + p < 0.05 vs CTRL; ++ p < 0.02 vs CTRL;              873 
+++ p < 0.01 vs CTRL; ++++ p< 0.005 vs CTRL; +++++ p < 0.001 vs CTRL; * p < 0.05 SLN vs 874 
PTX; ** p < 0.02 SLN vs PTX; *** p < 0.001 SLN vs PTX. 875 
 876 
Figure 11: cytotoxicity against O625 cells. + p < 0.05 vs CTRL; ++ p < 0.02 vs CTRL; +++ p < 877 
0.01 vs CTRL; ++++ p< 0.005 vs CTRL; +++++ p < 0.001 vs CTRL; * p < 0.05 SLN vs PTX. 878 
 879 
Figure 12: cytotoxicity against U87 cells. + p < 0.01 vs CTRL; ++ p < 0.002 vs CTRL; +++ p < 880 
0.005 vs CTRL; * p < 0.05 SLN vs PTX; ** p < 0.02 SLN vs PTX; *** p < 0.001 SLN vs PTX. 881 
 882 
Figure 13: cytotoxicity against hCMEC/D3 cells. + p < 0.01 vs CTRL; ++ p < 0.005 vs CTRL 883 
 * p < 0.05 SLN vs PTX; ** p < 0.002 SLN vs PTX. 884 
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SLN Na-BA* (mg) 
PVA 
9000 
(mg) 
PTX 
(mg) 
CHOL 
(mg) 
ST 
(mg) 
GCS 
(mg) 
Mean diameter 
(nm) 
(PDI) 
Zeta 
Potential 
(mV) 
0 53 37.5 3 - - - 299.2 ± 0.3 (0.053) - 3.04 ± 0.56 
1 53 37.5 3 0.5 - - 
381.3 ± 20.4 
(0.152) 
- 3.30 ± 0.47 
2 53 37.5 4.5 0.5 - - 
386.4 ± 12.3 
(0.167) 
- 3.34 ± 0.79 
3 53 37.5 6 0.5 - - 
383.8 ± 23.2 
(0.085) 
- 3.41 ± 0.60 
4 53 37.5 3 - 3 - 
345.6 ± 9.7 
(0.089) 
7.85 ± 0.91 
5 53 37.5 3 - 6 - 
537.7 ± 13.5 
(0.105) 
14.37 ± 1.52 
6 53 37.5 3 0.5 3 - 
581.0 ± 61.1 
(0.201) 
8.03 ± 0.70 
7 53 25 3 0.5 3 - 
507.0 ± 10.5 
(0.099) 
10.19 ± 0.69 
8 53 37.5 3 0.75 3 - 
579.6 ± 7.7 
(0.115) 
10.40 ± 1.14 
9 53 37.5 4.5 0.5 3 - 
548.6 ± 20.2 
(0.130) 
9.07 ± 2.45 
10 53 37.5 6 0.5 3  
984.9 ± 93.6 
(0.103) 
7.65 ± 0.85 
11 53 37.5 6 - - 10 
553.5 ± 5.7 
(0.196) 
16.90 ± 4.13 
12 53 37.5 6 - - 16 
488.4 ± 19.3 
(0.213) 
23.79 ± 1.81 
13 53 50 6 - - 10 
469.6 ± 3.8 
(0.202) 
15.46 ± 2.32 
14 53 100 6 - - 10 
624.3 ± 16.1 
(0.205) 
15.64 ± 3.12 
15 53 37.5 4.5 0.5 - 10 
462.7 ± 32.3 
(0.227) 
18.21 ± 1.67 
16 53 37.5 6 0.5 - 10 
476.4 ± 8.4 
(0.196) 
20.28 ± 1.10 
17 53 50 6 0.5 - 10 
374.5 ± 4.8 
(0.232) 
19.56 ± 1.73 
 886 
Table 1 887 
  888 
41 
 
SLN PTX EE% PTX LOADING (µg PTX/mg BA) 
0 78 ± 4 47 ± 2 
1 85 ± 5 50 ± 3 
2 89 ± 3 80 ± 3 
3 90 ± 3 108 ± 4 
4 70 ± 6 42 ± 4 
5 25 ± 3 16 ± 2 
6 87 ± 4 52 ± 2 
7 98 ± 2 60 ± 1 
8 65 ± 6 40 ± 4 
9 92 ± 4 82 ± 3 
11 77 ± 2 92 ± 2 
12 81 ± 4 98 ± 5 
13 52 ± 5 62 ± 6 
14 24 ± 3 28 ± 3 
15 83 ± 4 74 ± 3 
16 83 ± 3 100 ± 4 
17 75 ± 5 90 ± 6 
 889 
Table 2 890 
  891 
42 
 
 SLN 9  SLN 15  SLN 16  SLN 17 
7 days 
Size (nm) 682.4 ± 15.1 783.2 ± 74.3 554.2 ± 9.5 500.1 ± 6.4 
%EE 92 ± 3 81 ± 2 80 ± 2 74 ± 3 
Zeta 
potential 
(mV) 
9.15 ± 0.85 13.4 ± 0.9 15.9 ± 2.8 18.3 ± 1.6 
30 days 
Size (nm) 1500.0 ± 21.6 799.7 ± 63.2 598.1 ± 14.6 599.2 ± 9.5 
%EE 91 ± 4 80 ± 3 79 ± 3 73 ± 2 
Zeta 
potential 
(mV) 
9.05 ± 0.54 11.6 ± 1.4 14.5 ± 3.3 14.4 ± 3.1 
60 days 
Size (nm) 1536.8 ± 39.2 933.8 ± 17.9 669.8 ± 27.3 686.1 ± 12.4 
%EE 89 ± 4 80 ± 3 71 ± 2 73 ± 2 
Zeta 
potential 
(mV) 
9.07 ± 0.65 10.7 ± 2.1 13.9 ± 3.4 12.9 ± 4.1 
 892 
Table 3 893 
  894 
43 
 
 SLN 9 SLN 15 SLN 16 SLN 17 
Mean diameter (nm) 842.0 ± 17.9 632.4 ± 18.4 592.3 ± 18.0 408.4 ± 5.8 
Zeta potential (mV) 8.66 ± 1.02 18.56 ± 1.34 19.68 ± 1.98 19.87 ± 1.45 
PTX  EE% 88 ± 3 81 ± 2 83 ± 2 89 ± 3 
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 923 
